Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes

Nature

Volumn 491, Issue 7424, 2012, Pages 399-405

  Biankin, Andrew V ^a,b,c   Waddell, Nicola ^d   Kassahn, Karin S ^d   Gingras, Marie Claude ^e   Muthuswamy, Lakshmi B ^f   Johns, Amber L ^a   Miller, David K ^d   Wilson, Peter J ^d   Patch, Ann Marie ^d   Wu, Jianmin ^a   Chang, David K ^a,b,c   Cowley, Mark J ^a   Gardiner, Brooke B ^d   Song, Sarah ^d   Harliwong, Ivon ^d   Idrisoglu, Senel ^d   Nourse, Craig ^d   Nourbakhsh, Ehsan ^d   Manning, Suzanne ^d   Wani, Shivangi ^d   Gongora, Milena ^d   Pajic, Marina ^a   Scarlett, Christopher J ^a,g   Gill, Anthony J ^a,h,i   Pinho, Andreia V ^a   Rooman, Ilse ^a   Anderson, Matthew ^d   Holmes, Oliver ^d   Leonard, Conrad ^d   Taylor, Darrin ^d   Wood, Scott ^d   Xu, Qinying ^d   Nones, Katia ^d   Fink, J Lynn ^d   Christ, Angelika ^d   Bruxner, Tim ^d   Cloonan, Nicole ^d   Kolle, Gabriel ^j   Newell, Felicity ^d   Pinese, Mark ^a   Mead, R Scott ^a,k   Humphris, Jeremy L ^a   Kaplan, Warren ^a   Jones, Marc D ^a   Colvin, Emily K ^a   Nagrial, Adnan M ^a   Humphrey, Emily S ^a   Chou, Angela ^a,k   Chin, Venessa T ^a   Chantrill, Lorraine A ^a   Mawson, Amanda ^a   Samra, Jaswinder S ^h   Kench, James G ^a,i,l   Lovell, Jessica A ^a   Daly, Roger J ^a   Merrett, Neil D ^b,m   Toon, Christopher ^a   Epari, Krishna ⁿ   Nguyen, Nam Q ^o   Barbour, Andrew ^d   Zeps, Nikolajs ^p,q   Kakkar, Nipun ^e   Zhao, Fengmei ^e   Wu, Yuan Qing ^e   Wang, Min ^e   Muzny, Donna M ^e   Fisher, William E ^e   Brunicardi, F Charles ^r   Hodges, Sally E ^e   Reid, Jeffrey G ^e   Drummond, Jennifer ^e   Chang, Kyle ^e   Han, Yi ^e   Lewis, Lora R ^e   Dinh, Huyen ^e   Buhay, Christian J ^e   Beck, Timothy ^f   Timms, Lee ^f   Sam, Michelle ^f   Begley, Kimberly ^f   Brown, Andrew ^f   Pai, Deepa ^f   Panchal, Ami ^f   Buchner, Nicholas ^f   De Borja, Richard ^f   Denroche, Robert E ^f   Yung, Christina K ^f   Serra, Stefano ^s   Onetto, Nicole ^f   Mukhopadhyay, Debabrata ^t   Tsao, Ming Sound ^s   Shaw, Patricia A ^s   Petersen, Gloria M ^t   Gallinger, Steven ^s,u   Hruban, Ralph H ^v   Maitra, Anirban ^v   Iacobuzio Donahue, Christine A ^v   Schulick, Richard D ^v   Wolfgang, Christopher L ^v   Morgan, Richard A ^v   Lawlor, Rita T ^w   Capelli, Paola ^x   Corbo, Vincenzo ^w   Scardoni, Maria ^x   Tortora, Giampaolo ^w   Tempero, Margaret A ^y   Mann, Karen M ^z   Jenkins, Nancy A ^z   Perez Mancera, Pedro A ^aa,ab   Adams, David J ^ac   Largaespada, David A ^ad   Wessels, Lodewyk F A ^ae   Rust, Alistair G ^ac   Stein, Lincoln D ^f   Tuveson, David A ^aa,ab   Copeland, Neal G ^z   Musgrove, Elizabeth A ^a,af   Scarpa, Aldo ^w,x   Eshleman, James R ^v   Hudson, Thomas J ^f   Sutherland, Robert L ^a,af   Wheeler, David A ^e   Pearson, John V ^d   McPherson, John D ^f   Gibbs, Richard A ^e   Grimmond, Sean M ^d   more..

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b BANKSTOWN LIDCOMBE HOSPITAL   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

^g UNIVERSITY OF NEWCASTLE   (Australia)

^h ROYAL NORTH SHORE HOSPITAL   (Australia)

ⁱ UNIVERSITY OF SYDNEY   (Australia)

^j Life Technologies   (Australia)

^k ST VINCENT S HOSPITAL   (Australia)

^l ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^m UNIVERSITY OF WESTERN SYDNEY   (Australia)

ⁿ FREMANTLE HOSPITAL   (Australia)

^o ROYAL ADELAIDE HOSPITAL   (Australia)

^p UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^q St John of God Pathology   (United States)

^r UNIVERSITY OF CALIFORNIA   (United States)

^s UNIVERSITY HEALTH NETWORK   (Canada)

^t MAYO CLINIC   (United States)

^u MOUNT SINAI HOSPITAL   (Canada)

^v JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^w UNIVERSITY AND HOSPITAL TRUST OF VERONA   (Italy)

^x UNIVERSITY OF VERONA   (Italy)

^y UNIVERSITY OF CALIFORNIA   (United States)

^z HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^aa IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^ab Cancer Research UK ^*  (United Kingdom)

^ac WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^ad UNIVERSITY OF MINNESOTA   (United States)

^ae NETHERLANDS CANCER INSTITUTE   (Netherlands)

^af UNIVERSITY OF NEW SOUTH WALES   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARID1A PROTEIN; ARID2 PROTEIN; ATM PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPC1 PROTEIN; K RAS PROTEIN; MAGEA6 PROTEIN; MAP2K4 PROTEIN; MLL3 PROTEIN; NALCN PROTEIN; PROTEIN; PROTEIN P53; SF3B1 PROTEIN; SF3BI PROTEIN; SLC1LA4 PROTEIN; SLCI6A4 PROTEIN; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; UNCLASSIFIED DRUG; ZIM2 PROTEIN;

CANCER; CHROMOSOME; DISEASE TREATMENT; GENE EXPRESSION; GENOME; HETEROGENEITY; MOLECULAR ANALYSIS; MUTATION; TUMOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AXON GUIDANCE PATHWAY GENE; CANCER MODEL; COPY NUMBER VARIATION; DISEASE SEVERITY; DNA MODIFICATION; EXOME; GENE DELETION; GENE INSERTION; GENE MUTATION; GENE SEQUENCE; GENETIC HETEROGENEITY; HUMAN; MAJOR CLINICAL STUDY; MISSENSE MUTATION; MOUSE; MUTAGENESIS; MUTATIONAL ANALYSIS; NERVE FIBER; NONHUMAN; NONSENSE MUTATION; ONCOGENE; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIGNAL TRANSDUCTION; TRANSPOSON;

ANIMALIA; MURINAE;

EID: 84869091997     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature11547     Document Type: Article

References (38)

1. Jemal, A., Siegel, R., Xu, J. & Ward, E. Cancer statistics, 2010. CA Cancer J. Clin. 60, 277-300 (2010).
2. Butturini, G. et al. Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials. Arch. Surg. 143, 75-83 (2008).
3. Neoptolemos, J. P. et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. J. Am. Med. Assoc. 304, 1073-1081 (2010).
4. Jones, S. et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321, 1801-1806 (2008).
5. International Cancer Genome Consortium. International network of cancer genome projects. Nature 464, 993-998 (2010).
6. Biankin, A. V. et al. Expression of S100A2 calcium-binding protein predicts response to pancreatectomy for pancreatic cancer. Gastroenterology 137, 558-568 (2009).
7. Chang, D. K. et al. Margin clearance and outcome in resected pancreatic cancer. J. Clin. Oncol. 27, 2855-2862 (2009).
8. Jamieson, N. B. et al. A prospective comparison of the prognostic value of tumorand patient-related factors in patients undergoing potentially curative surgery for pancreatic ductal adenocarcinoma. Ann. Surg. Oncol. 18, 2318-2328 (2011).
9. Wang, L. et al. Whole-exome sequencing of human pancreatic cancers and characterization of genomic instability caused by MLH1 haploinsufficiency and complete deficiency. Genome Res. 22, 208-219 (2012).
10. Song, S. et al. qpure: A tool to estimate tumor cellularity fromgenome-wide singlenucleotide polymorphism profiles. PLoS ONE 7, e45835 (2012).
11. Samuel, N. & Hudson, T. J. The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma. Nature Rev. Gastroenterol. Hepatol. 9, 77-87 (2012).
12. Dees, N. D. et al. MuSiC: Identifying mutational significance in cancer genomes. Genome Res. 22, 1589-1598 (2012).
13. Roberts, N. J. et al. ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov. 2, 41-46 (2011).
14. Mermel, C. H. et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 12, R41 (2011).
15. Sun, W. et al. Integrated study of copy number states and genotype calls using high-density SNP arrays. Nucleic Acids Res. 37, 5365-5377 (2009).
16. Campbell, P. J. et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467, 1109-1113 (2010).
17. Mann, K. M. et al. SleepingBeautymutagenesis reveals cooperatingmutations and pathways in pancreatic adenocarcinoma. Proc. Natl Acad. Sci. USA 109, 5934-5941 (2012).
18. Pérez-Mancera, P. A. et al. The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature 486, 266-270 (2012).
19. Cheung, H. W. et al. Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovariancancer. Proc.Natl Acad. Sci. USA 108, 12372-12377 (2011).
20. Mehlen, P., Delloye-Bourgeois, C. & Chedotal, A. Novel roles for Slits and netrins: axonguidance cues as anticancer targets? Nature Rev. Cancer 11, 188-197 (2011).
21. Sabatier, C. et al. The divergent Robo family protein rig-1/Robo3 is a negative regulator of slit responsiveness required for midline crossing by commissural axons. Cell 117, 157-169 (2004).
22. Trusolino, L. & Comoglio, P. M. Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nature Rev. Cancer 2, 289-300 (2002).
23. Birnbaum, D. J. et al. Genome profiling of pancreatic adenocarcinoma. Genes Chromosom. Cancer 50, 456-465 (2011).
24. Bamford, S. et al. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br. J. Cancer 91, 355-358 (2004).
25. Jones, S. et al.Somaticmutations in the chromatin remodeling geneARID1A occur in several tumor types. Hum. Mutat. 33, 100-103 (2012).
26. Varela, I. et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469, 539-542 (2011).
27. Comoglio, P. M. & Trusolino, L. Invasive growth: from development to metastasis. J. Clin. Invest. 109, 857-862 (2002).
28. Chédotal, A., Kerjan, G. & Moreau-Fauvarque, C.Thebrainwithin the tumor:newroles for axon guidance molecules in cancers. Cell Death Differ. 12, 1044-1056 (2005).
29. Ong, C. K. et al. Exome sequencing of liver fluke-associated cholangiocarcinoma. Nature Genet. 44, 690-693 (2012).
30. Capparuccia, L. & Tamagnone, L. Semaphorin signaling in cancer cells and in cells of the tumor microenvironment-two sides of a coin. J. Cell Sci. 122, 1723-1736 (2009).
31. Müller, M. W. et al. Association of axon guidance factor semaphorin 3A with poor outcome in pancreatic cancer. Int. J. Cancer 121, 2421-2433 (2007).
32. Ellis, L. M.The role of neuropilins in cancer.Mol. Cancer Ther. 5, 1099-1107 (2006).
33. Kikuchi, K. et al. In vitro and in vivo characterization of a novel semaphorin 3A inhibitor, SM-216289 or xanthofulvin. J. Biol. Chem. 278, 42985-42991 (2003).
34. Cao, Y., DePinho, R. A., Ernst, M. & Vousden, K. Cancer research: past, present and future. Nature Rev. Cancer 11, 749-754 (2011).
35. Pajic, M., Scarlett, C. J., Chang, D. K., Sutherland, R. L. & Biankin, A. V. Preclinical strategies to define predictive biomarkers for therapeutically relevant cancer subtypes. Hum. Genet. 130, 93-101 (2011).
36. Biankin, A. V. & Hudson, T. J. Somatic variation and cancer: therapies lost in the mix. Hum. Genet. 130, 79-91 (2011).
37. Kris, M. G., Meropol, N. J. & Winer, E. P. (eds) . Accelerating Progress Against Cancer: ASCO's Blueprint for Transforming Clinical and Translational Cancer Research (Am. Soc. Clin. Oncol., 2011).
38. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545-15550 (2005).